Major surgery patientsa (n = 250) | Nonmajor surgery patientsa (n = 461) | P-value | |
---|---|---|---|
Ageb, years, mean ± SD | 73.1 ± 8.8 | 74.8 ± 9.7 | 0.023 |
<65 | 37 (14.8) | 55 (11.9) | |
65 to < 75 | 103 (41.2) | 146 (31.7) | |
≥75 | 110 (44.0) | 260 (56.4) | |
Sex | |||
Male | 153 (61.2) | 276 (59.9) | 0.729 |
Female | 97 (38.8) | 185 (40.1) | |
Weight, kg, mean ± SD | 75.6 ± 16.4 | 75.9 ± 16.2 | 0.808 |
BMI, kg/m2, mean ± SD | 26.7 ± 4.4 | 27.0 ± 5.0 | 0.415 |
Atrial fibrillation | 229 (91.6) | 437 (94.8) | 0.095 |
CrCL, mL/min, mean ± SD | 70.7 ± 25.9 | 66.3 ± 27.8 | 0.052 |
≤50 | 52 (20.8) | 115 (24.9) | |
Hypertension | 186 (74.4) | 350 (75.9) | 0.653 |
Diabetes mellitus | 49 (19.6) | 132 (28.6) | 0.008 |
Dyslipidaemia | 108 (43.2) | 182 (39.5) | 0.335 |
Coronary heart disease | 41 (16.4) | 86 (18.7) | 0.454 |
Valvular heart disease | 46 (18.4) | 81 (17.6) | 0.783 |
Congestive heart failure | 33 (13.2) | 64 (13.9) | 0.800 |
HAS-BLED score, mean ± SD | 2.0 ± 1.0 | 1.8 ± 1.1 | 0.134 |
CHA2DS2-VASc score, mean ± SD | 3.5 ± 1.5 | 3.6 ± 1.5 | 0.476 |
Edoxaban dose | |||
30 mg/day | 86 (34.4) | 158 (34.3) | 0.973 |
60 mg/day | 162 (64.8) | 302 (65.5) | |
Other | 2 (0.8) | 1 (0.2) | |
Antiplatelet agents | 38 (15.2) | 52 (11.3) | 0.133 |